Taxane chemotherapy vs antiandrogen agents as first-line therapy for metastatic castration-resistant prostate cancer
Author:
Affiliation:
1. Dana Farber Cancer Institute; Boston MA USA
2. STATinMED Research; Ann Arbor MI USA
3. Department of Surgery; Center for Innovation & Outcomes Research; Columbia University; New York NY USA
4. Sanofi; Bridgewater NJ USA
Funder
Sanofi
Olga Ucar of MediTech Media
Publisher
Wiley
Subject
Urology
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/bju.14152/fullpdf
Reference30 articles.
1. Sequencing of agents in castration-resistant prostate cancer;Lorente;Lancet Oncol,2015
2. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer;Tannock;N Engl J Med,2004
3. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer;Petrylak;N Engl J Med,2004
4. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study;Ryan;Lancet Oncol,2015
5. Enzalutamide in metastatic prostate cancer before chemotherapy;Beer;N Engl J Med,2014
Cited by 16 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Impact of Novel Agents on Patient Characteristics, Treatment Patterns, and Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer;Anticancer Research;2024-06-26
2. Novel hormonal therapy versus standard of care—A registry-based comparative effectiveness evaluation for mCRPC-patients;PLOS ONE;2024-02-14
3. Diethyldithiocarbamate copper nanoparticle overcomes resistance in cancer therapy without inhibiting P-glycoprotein;Nanomedicine: Nanotechnology, Biology and Medicine;2023-01
4. Prognostic significance of risk stratification in CHAARTED and LATITUDE studies among Japanese men with castration-resistant prostate cancer;Prostate International;2022-03
5. Real‐world first‐line systemic therapy patterns in metastatic castration‐resistant prostate cancer;BJUI Compass;2021-12-14
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3